Tarsus Pharmaceuticals enters July with a notable divergence: options traders have swung sharply toward calls just as short sellers trim positions modestly — a combination that places the stock in an unusually bullish-leaning setup heading into its August 5 earnings.
The options shift is the week's most striking signal. The put/call ratio has collapsed to 0.83, nearly three standard deviations below its 20-day average of 1.78 — a move that marks the most call-heavy reading this stock has seen in months. For context, the ratio spent most of June above 1.85, consistent with hedgers holding relatively cautious positions. The abrupt reversal over the past two sessions suggests fresh call buying, not simply put liquidation. At the same time, borrow availability remains extremely loose — sitting near 1,917% of short interest, well above its 52-week low of 350%, meaning shorting the stock is cheap and easy. Cost to borrow is just 0.55%, up roughly 18% on the week but still firmly in "easy borrow" territory. The lending market imposes no friction on new short positions.
Short interest tells a more nuanced story than the options signal implies. At 11.9% of free float — roughly 5.05 million shares — the short book is elevated but has been drifting lower. It fell about 2.8% over the past week and is essentially flat over the past month after an early-June creep higher. The ORTEX short score of 58.8 has eased gradually from above 59.7 ten days ago, consistent with modest short covering rather than a coordinated squeeze. With 8.9 days to cover on the official FINRA data, a disorderly unwind would require a meaningful catalyst — one that isn't yet visible in the lending data.
The Street remains constructively positioned, though the most recent analyst activity is dated. The last formal move on record was HC Wainwright reiterating its Buy and $88 target in early May; before that, Oppenheimer raised its target to $105 and Guggenheim lifted to $90 in February, both maintaining positive ratings. The consensus mean target of $94 implies roughly 49% upside from the current price of $62.94. Goldman Sachs sits at Neutral — the only notable dissenter in the visible coverage universe, with a $51 target raised from May 2025, though that figure now looks dated relative to where the stock trades. EV/EBITDA has compressed about 26% over the past 30 days, now near 35x, while the P/E of 61x has shed more than 22 points over the same period — reflecting earnings growth running faster than the share price. EPS momentum factor scores rank in the 97th and 99th percentiles on 30- and 90-day windows respectively, underscoring that estimate revisions have been consistently positive heading into the next print.
Insider activity adds a mild note of caution to the otherwise bullish positioning picture. CEO Bobak Azamian sold roughly $615,000 worth of stock on June 17, across two transactions. CFO Jeff Farrow received a 27,881-share award on June 15 and then sold 14,396 shares the following day for approximately $877,000. Director William Link sold just over $776,000 across two transactions. These appear largely to be award-related disposals rather than discretionary selling — the 90-day net insider position is actually positive at approximately $4.8 million, suggesting the preponderance of recent activity has been on the buy side over the full quarter window. Still, the cluster of sales within a narrow window just ahead of earnings is worth noting.
TARS fell 6.2% on the day of its most recent earnings event on June 25, and prior prints have also produced small negative reactions. The August 5 report is the next defined event; between now and then, the divergence between a sharply improved options sentiment and still-elevated short interest of nearly 12% of float is the central dynamic worth tracking.
See the live data behind this article on ORTEX.
Open TARS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
